Equillium Inc. Company Profile
NASDAQ: EQHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
Equillium at a glance
Equillium Inc. (NASDAQ: EQ) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in La Jolla, CA. Equillium is led by Mr. Bruce Steel and employs about 14 people. The company's shares have traded publicly since 2018.
At a market capitalization of $91.3 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001746466, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Equillium do?
Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases. It also develops EQ302, a bi-specific inhibitor of IL-15 and IL-21 formulated for oral delivery for the treatment of celiac diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
Business description based on the company's public filings.
Company information
- Legal name
- Equillium Inc.
- Ticker
- NASDAQ: EQ
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Bruce Steel
- Employees
- 14
- Headquarters
- 2223 Avenida De La Playa, La Jolla, CA, United States
- Phone
- 858 240 1200
- Website
- equilliumbio.com
- IPO year
- 2018
- Market cap
- $91.31M
- SEC CIK
- 0001746466
- Latest annual report
- 10-K · Mar 25, 2026
Companies similar to Equillium
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| RLYBRallybio Corporation | 16.99 | +0.35% | $90.26M | vs EQ |
| OKUROnKure Therapeutics Inc. Class A | 2.30 | -2.13% | $93.14M | vs EQ |
| MISTMilestone Pharmaceuticals Inc. | 0.7121 | -5.96% | $88.66M | vs EQ |
| CTORCitius Oncology Inc. | 0.835 | -2.45% | $88.31M | vs EQ |
| TELOTelomir Pharmaceuticals Inc. | 1.15 | +2.68% | $84.66M | vs EQ |
| BMEABiomea Fusion Inc. | 1.37 | +3.79% | $99.05M | vs EQ |
| PLYXPolaryx Therapeutics Inc. | 2.00 | -4.31% | $99.69M | vs EQ |
| PMNProMIS Neurosciences Inc. | 9.15 | +0.33% | $82.05M | vs EQ |